A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy
PHASE3CompletedINTERVENTIONAL
Enrollment
939
Participants
Timeline
Start Date
June 30, 2000
Study Completion Date
December 31, 2006
Conditions
AnemiaBreast NeoplasmsQuality of Life
Interventions
DRUG
epoetin alfa
All Listed Sponsors
lead
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
INDUSTRY
NCT00211133 - A Study to Evaluate the Impact of Maintaining Hemoglobin Levels Using Epoetin Alfa in Patients With Metastatic Breast Cancer Receiving Chemotherapy | Biotech Hunter | Biotech Hunter